Artikel ; Online: Palbociclib plus letrozole induces a complete metabolic response in metastatic breast cancer patient with idiopathic thrombocytopenia.
2022 Band 113, Heft 6, Seite(n) 376–379
Abstract: Breast cancer is still the leading cause of cancer-related deaths among women aged 20-59 and metastatic breast cancer remains an incurable disease. The therapeutic paradigm of patients with HR-positive HER2-negative metastatic breast cancer has been ... ...
Abstract | Breast cancer is still the leading cause of cancer-related deaths among women aged 20-59 and metastatic breast cancer remains an incurable disease. The therapeutic paradigm of patients with HR-positive HER2-negative metastatic breast cancer has been expanded by the introduction of the inhibitors of cyclin-dependent kinases 4/6. Three compounds, palbociclib, ribociclib, and abemaciclib, have already been approved by the Food and Drug Administration (FDA) for use together with endocrine therapy; abemaciclib is also approved as a single agent. In the first-line setting, all three agents - together with an aromatase inhibitor (AI) - substantially prolonged progression-free survival. Hematologic toxicities are the most common adverse events associated with CDK4/6i, mainly with palbociclib and ribociclib. Due to the hematologic toxicity, the prescribing information of palbociclib (P) recommends monitoring complete blood counts before starting therapy and at the beginning of each cycle, as well as on day 15 of the first 2 cycles. However, there are no guidelines regarding the management of patients candidate to CDK4/6i who have bone marrow impairment. Neutropenia frequently occurs during the treatment with P, whereas thrombocytopenia represents a rare event. We here report a case of a 60-year-old woman with idiopathic thrombocytopenia treated with P plus letrozole, who presented a metabolic complete response. |
---|---|
Mesh-Begriff(e) | Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Breast Neoplasms/complications ; Breast Neoplasms/drug therapy ; Female ; Humans ; Letrozole/therapeutic use ; Middle Aged ; Piperazines ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Pyridines ; Thrombocytopenia/chemically induced ; Thrombocytopenia/drug therapy |
Chemische Substanzen | Piperazines ; Protein Kinase Inhibitors ; Pyridines ; Letrozole (7LKK855W8I) ; palbociclib (G9ZF61LE7G) |
Sprache | Englisch |
Erscheinungsdatum | 2022-06-25 |
Erscheinungsland | Italy |
Dokumenttyp | Case Reports ; Journal Article |
ZDB-ID | 138266-4 |
ISSN | 2038-1840 ; 0034-1193 |
ISSN (online) | 2038-1840 |
ISSN | 0034-1193 |
DOI | 10.1701/3827.38111 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.B 193: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.